Effects of low doses of aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane production and 6-keto-PGF1 alpha excretion in healthy subjects

Thromb Res. 1987 Feb 15;45(4):355-61. doi: 10.1016/0049-3848(87)90224-6.

Abstract

To compare the long term effects of two low doses of aspirin taken daily, we performed a placebo-controlled cross-over study in 19 normal subjects. Aspirin 10 mg daily for 3 weeks caused a significant inhibition by 61 +/- 12 percent of platelet thromboxane B2 generation but had no effect on the Simplate bleeding time. Aspirin 30 mg daily for 3 weeks reduced thromboxane B2 production by 94 +/- 5 percent and caused a significant prolongation of the bleeding time, 1.6 times the control value. No cumulative inhibitory effects were observed after the first week of treatment. Both doses did not effect the urinary excretion of 6-keto-PGF1 alpha.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • 6-Ketoprostaglandin F1 alpha / urine*
  • Adult
  • Aspirin / administration & dosage*
  • Bleeding Time*
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Male
  • Middle Aged
  • Platelet Function Tests*
  • Thromboxane A2 / blood
  • Thromboxane B2 / blood
  • Thromboxanes / biosynthesis
  • Thromboxanes / blood*
  • Time Factors

Substances

  • Thromboxanes
  • Thromboxane B2
  • Thromboxane A2
  • 6-Ketoprostaglandin F1 alpha
  • Aspirin